In his weekly clinical update Dr. Griffin discusses human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks, changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States, updates on COVID-19–related mortality, impact of community masking on COVID-19, effectiveness of the COVID-19 vaccines against hospitalization with Omicron sub-lineages BA.4 and BA.5 in England, cardiovascular outcomes after Tixagevimab and Cilgavimab use for pre-exposure prophylaxis against COVID-19, how Paxlovid is associated with decreased hospitalization rate among adults with COVID-19, inside the mind of an anti-paxxer, and angiotensin receptor blockers for the treatment of COVID-19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Human monkeypox virus infection in women and non-binary individuals (The Lancet) Changes in population immunity against infection and severe disease from variants (Medrxiv) Updates on COVID-19 related mortality (CDC) Impact of community masking on COVID-19 (Science) Effectiveness of the COVID-19 vaccines against hospitalization (The Lancet) Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis (CID) Bebtelovimab fact sheet for providers (FDA) Paxlovid associated with decreased hospitalization among adults (CDC) Inside the mind of an Anti-Paxxer (The Atlantic) Paxlovid patient eligbiliity screening checklist (FDA) Angiotensin receptor blockers for the treatment of COVID-19 (BMJ) Long COVID treatment research study (Stanford) HHS long COVID study (pdf) Biden administration requests long COVID fu Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 957 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks, changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States, updates on COVID-19–related mortality, impact of community masking on COVID-19, effectiveness of the COVID-19 vaccines against hospitalization with Omicron sub-lineages BA.4 and BA.5 in England, cardiovascular outcomes after Tixagevimab and Cilgavimab use for pre-exposure prophylaxis against COVID-19, how Paxlovid is associated with decreased hospitalization rate among adults with COVID-19, inside the mind of an anti-paxxer, and angiotensin receptor blockers for the treatment of COVID-19.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Human monkeypox virus infection in women and non-binary individuals (The Lancet)
• Changes in population immunity against infection and severe disease from variants (Medrxiv)
• Updates on COVID-19 related mortality (CDC)
• Impact of community masking on COVID-19 (Science)
• Effectiveness of the COVID-19 vaccines against hospitalization (The Lancet)
• Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis (CID)
• Bebtelovimab fact sheet for providers (FDA)
• Paxlovid associated with decreased hospitalization among adults (CDC)
• Inside the mind of an Anti-Paxxer (The Atlantic)
• Paxlovid patient eligbiliity screening checklist (FDA)
• Angiotensin receptor blockers for the treatment of COVID-19 (BMJ)
• Long COVID treatment research study (Stanford)
• HHS long COVID study (long-covid-report.pdf">pdf)
• Biden administration requests long COVID fu
• Contribute to our MicrobeTV fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 957
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv